Evaluating Inhibitory Effects of Paclitaxel and Vitamin D₃ Loaded Poly Lactic Glycolic Acid Co-Delivery Nanoparticles on the Breast Cancer Cell Line

Sepideh Khodaverdi¹, Alireza Jafari²-*, Farahnaz Movahedzadeh³-⁴, Fateme Madani⁵, Arshid Yousefi Avarvand⁶, Siavash Falahatkar²

¹Department of Obstetrics and Gynecology, Fellowship of Laparoscopy, Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
²Urology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
³Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
⁴Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
⁵Department of Pharmaceutical Sciences, College of Pharmacy University of Illinois at Chicago, Chicago, Illinois, USA.
⁶Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁷Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Purpose: Paclitaxel (PTX) has transpired as a significant agent in the treatment of breast cancer. Meanwhile, polyactic glycolic acid (PLGA) nanoparticles (NPs) are able to increase the anti-cancer effect of the PTX in the blood.

Methods: Nano-precipitation was used to prepare the PLGA-PTX-VitD3 co-delivery NPs. Drug loading, encapsulation efficiency, in vitro release profile, cell viability, migration, apoptosis, and bcl2 expression of NPs were evaluated.

Results: The average size of co-delivery NPs was 231 ± 46 nm. Observed was a controlled release of the PTX and vitamin D3 from co-delivery NPs between 0.5 and 240 hours. MTT showed the ability of 8 μg.mL⁻¹ of co-delivery NPs to kill 50 % of the MCF-7; likewise, the co-delivery NPs prevented MCF-7 migration. The co-delivery NPs led 46.35 % MCF-7 to enter primary apoptosis. 60.8% of MCF-7 in the control group were able to enter the G (1) phase of the cell cycle. The co-delivery NPs increased expression of bax. In addition to its higher toxicity against MCF-7 than that of PTX, co-delivery NPs were able to release drugs continuously for a long period, which indeed increased the efficiency of the drugs.

Conclusion: The effect of co-delivery NPs on MCF-7 cell viability was different from that in other drugs. In fact, the co-deliver NPs were able to release drugs continuously for a long time, this could induce primary apoptosis in the MCF-7 and decrease the metastasis and toxicity of drugs.

Introduction

Breast cancer is among the most common neoplastic malignancies, and one of the leading causes of women's death in the world.¹ High instances of this malignancy is found in developed countries; the prevalence of breast cancer in Iran is lower than that of developed countries.² In spite of surgery, chemotherapy and radiotherapy as therapeutic options of this malignancy, mortality rate is still high among patients with breast cancer.³ Currently, the co-delivery of anti-cancer drugs has been developed by assistance of biodegradable nanoparticles (NPs) such as polyactic glycolic acid (PLGA) NPs.³⁴

PLGA NPs are one group of the commonly used polymers in manufacturing NPs thanks to their high adaptability to biological environments, ability to degrade into natural metabolites, lower toxicity and higher stability than that of liposomes and some other drug delivery systems. PLGA NPs also have the ability to modify their surface to prevent rapid absorption of this polymer by the reticuloendothelial system of the body. Toxicity and damaging the healthy tissues in the immediate area of the tumor are the result of using high doses of the drug, meanwhile, a biodegradable and biocompatible amphiphilic polymer; in fact, PLGA increases the anti-cancer effect of the drug in the blood by increasing its circulation time. In addition, studies have shown that use of PLGA in active and inactive cerebellar drugs will increase their endocytosis. Moreover, the PLGA-made NPs are of

*Corresponding Author: Alireza Jafari, Fax: +98 13 33542460, Email: alireza_jafari@gums.ac.ir

© 2020 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
the most promising tools for transferring drugs and genes from the duct-brain. The poly vinyl alcohol (PVA) which modifies the size and distribution of small size in NPs is also one of the most widely used polymers for stabilizing NPs. Studies show that PVA is tightly connected to PLGA; the justification for this process is the hydrophobic link established between the hydroxyl functional group of PVA. The PLGA-PVA, which amongst others is one of the most successful polymers for making polymer NPs, could be a suitable candidate for delivery and controlled release of anti-cancer drugs such as paclitaxel (PTX). PTX is one of the new anti-cancer drugs used for many human cancers including ovarian and breast cancers. This molecule facilitates accumulation of microtubules from tubulin dimers and stabilizes them by preventing the de-polymerization of microtubules. Preventing the reorganization of the active and natural network of microtubules, this stability is essential for vital interphase and mitotic cell transplantation. In addition, PTX induces an abnormal or cluster arrangement of microtubules during the cell cycle, leading to the formation of multiple lobes of microtubules during mitosis. PTX, in spite of its therapeutic effect, causes side effects. Short metabolized half-life and membrane transducers preventing the concentration of the drug in the cell make repeated use of relatively high doses necessary to achieve the required concentration during the appropriate time periods, which in turn leads to toxicity. However, studies have shown that combination of 1, 25 dihydroxy cholecalciferol (VitD3) and PTX can also enhance anti-tumor activity and accelerate apoptosis in breast cancer. Evidently, many studies have shown that VitD3 has anticancer effects on many types of cancer cells, it modulates the immune system and controls the pathways, increases apoptosis, decreases cell growth, and regulates biological processes such as angiogenesis and the production of extracellular matrix as well. These effects result from the inhibition of the G1/S phase of the cell cycle and the effect on many activity regulatory of the cycling. VitD3 reduces the expression of anti-apoptotic proteins, and genes involved in the proliferation of uterine fibroids; and the production of extracellular matrix proteins.

There is no study with respect to the anti-cancer effects of the PLGA-PTX-VitD3 co-delivery NPs on bax expression. We combined the VitD3 and PTX to enhance the anti-cancer function, prolonged release, reduced toxicity, increased expression of bax gene. The cytotoxicity of VitD3 and PTX loaded PLGA NPs against MCF-7 cell lines were examined by MTT method and calculated IC50. The apoptosis, proliferative effects of NPs and the rate of expression of the bax genes were also compared.

Materials and Methods

Cell culture

MCF-7 human breast cancer cell line was cultured in Dulbecco’s modified Eagle medium (Gibco™, DMEM) (Thermo Fisher Scientific, Waltham, MA, USA), containing 10% fetal calf serum (Gibco™ FCS) (Thermo Fisher Scientific, Waltham, MA, USA), and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, USA) 10000 units/ml at 37°C in a humidified atmosphere of 95% air and 5% CO2.

Preparation of PTX and VitD3-loaded PLGA NPs

Nano-precipitation method was used to prepare the PLGA-PTX-VitD3 co-delivery NPs. The solution of PVA polymer (Thermo Fisher Scientific, Waltham, MA, USA) 1% w/v was prepared in deionized water, as an aqueous phase, under continuous magnetic stirring (FAR TEST, HPMA700) at 70°C for 5 hours to obtain a homogenous solution; likewise, 50 mg of the PLGA (Sigma Aldrich, St. Louis, USA) and 5 mg of the PTX (Sigma Aldrich, St. Louis, USA) were dissolved in 10 mL, and 5 mL of acetone (Merck, Germany), respectively. Next, 1 mL of the VitD3 (Sigma Aldrich, St. Louis, USA) was added to acetone (0.1 % W/V). Subsequently, the PTX was poured in the PLGA solution. Afterward, organic phase was poured in the PVA (100 mL) and stirred overnight at room temperature (around 20 ± 2°C). After the evaporation of the organic phase, the NPs were collected by centrifugation (Eppendorf, MA, USA) at 12000 rpm for 30 minutes at 4°C and washed twice with deionized water.

Physicochemical properties of NPs

The hydrodynamic diameter and the median for NPs’ size were obtained using dynamic light scattering (DLS) and zeta potential analyzer (Malvern, UK). The morphology and diameter of NPs were screened by scanning electron microscopy (SEM) as an accelerating voltage of 20.0 kV (Philips XL-30, OH, USA) after sputtering with gold. The NPs suspensions were diluted by sterile distilled water; they were then poured onto the copper plate. After the NPs dried at room temperature, they were coated with a thin layer of gold under vacuum. The diameter of NPs was measured by digitizer software. The Fourier-transform infrared spectroscopy (FTIR) (Nicolet, Magna-IR spectrometer 550) (Thermo Fisher Scientific, Waltham, MA, USA) was used to determine the chemical groups and the interaction between the particles.

Drug loading, encapsulation efficiency of NPs

Using UV-Visible spectroscopy at the wavelengths of 228 nm and 280 nm for PTX and, VitD3, respectively, we could obtain standard curves (Cecil CE 7250, England). The concentration of PTX and VitD3 encapsulated in the NPs was determined indirectly by measuring the amount of free drug in the supernatant by UV-VIS absorption being used. The supernatant was collected by centrifugation (Eppendorf, MA, USA) at 12000 rpm for 30 minutes at 4°C and washed twice with deionized water.

The encapsulation efficiency and drug loading were calculated using the equations below:
Encapsulation Efficiency (%):
\[
\frac{\text{Amount of drugs used to prepare NPs} - \text{amount of drugs in the supernatant}}{\text{Amount of drugs used to prepare NPs}} \times 100
\]

Drug loading (%):
\[
\frac{\text{Amount of drugs used to prepare NPs} - \text{amount of drugs in the supernatant}}{\text{Amount of drugs used to prepare NPs}} \times \frac{\text{weight of PGLA}}{100}
\]

**In vitro release studies**

In vitro release studies of all samples were performed in PBS (pH 7.4) containing 0.2% Tween 80. In detail, we measured 5 mg of each formulation dispersed in 1 mL of the release media. The suspension was put in a dialysis tubing (cut-off - 12.4 kDa, Cass # - D0405, Sigma Aldrich, USA) and placed in a falcon containing 50 mL of the release media. Afterwards, the falcons were placed in a shacking incubator at 37°C at 100 rpm (Labtech, S. Korea). At predetermined time intervals, falcon tubes were emptied and then replenished by fresh media. The concentration of drugs released from each sample was then determined via UV-VIS spectroscopy at the appropriate wavelengths. The kinetics of release model was Peppa-Korsmey. A cumulative release curve of percent drug release against time was then plotted.

**Cell viability assay**

MTT assay was applied to evaluate the cytotoxic effect of PLGA-PTX-VitD₃ co-delivery NPs, PTX, PLGA-PTX and, PLGA on MCF-7 breast cancer cells. To calculate the final concentration of the PLGA-PTX-VitD₃ co-delivery NPs, the mole scale of the NPs was converted to milligram scale and so the NPs were measured by weight balance (DORJE, KI-204, and China). Briefly, 1, 12.5, 25, 50, 100 and 200 µM of PLGA-PTX-VitD₃ co-delivery NPs were solved into the culture medium. The cells were seeded at a density of 1.2×10⁴ cells/mL, and incubated with PLGA-PTX-VitD₃ co-delivery NPs, PTX, PLGA-PTX and, PLGA for 24 hours, respectively. Then the DMEM was changed and cells were incubated with MTT solution (Sigma Aldrich, St. Louis, USA) (0.5 mg/mL) for 4 hours. In this study, control group was treated with DMSO 0.1%.

**Migration assay**

The MCF-7 cell lines were first grown in DMEM supplemented with 10% FBS to test migration assay, then seeded in 6-well plates. Next, the width of each well is scratched by sterile pipette tip (1 mm). The wells are washed by the culture medium and the picture of wounds is taken at 0 hour (NIKON, Inverted research microscope). Thereafter, medium was replaced with different concentrations of PLGA-PTX-VitD₃ co-delivery NPs, PTX and PLGA-PTX (IC₅₀ concentration) and the cells are allowed to migrate for 24 hours. After 24 hours, the picture of wound is taken from the same regions. The rate of migration (Rₑ) is analyzed by measuring the distance between the scratch edges with digitizer software.

The Rₑ is calculated by following equation: 
\[ Rₑ = \frac{(W₁ - W₂)}{t} \]

**Cell death with DAPI staining**

To evaluate cell death, the MCF-7 cell lines were grown in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin exposed to PLGA-PTX-VitD₃ co-delivery NPs (IC₅₀ concentration). The MCF-7 cells were harvested by trypsin-EDTA solution, and then were centrifuged at 2000 rpm for 5 minutes. The cells were stabilized with 4% paraformaldehyde. The cells were washed by adding 500 µL of 4, 6-diamidino-2-phenylindole (DAPI) reagent and were incubated. Next, the MCF-7 cells were centrifuged and after that the buffers (Buffer RLT Plus contains guanidine thiocyanate, buffer RW1 contains a small amount of guanidine thiocyanate, and buffer RW1 Contains ethanol) were added to cell suspension. Excitation wavelength were observed at 340/380 nm by fluorescent microscopy.

**Flow cytometer and cell cycle analysis**

To analyze the quantitative DNA content in MCF-7 culture cells exposed to PLGA-PTX-VitD₃ co-delivery NPs, PTX, and PLGA-PTX, the nucleic acid stain propidium iodide (PI) was used by flow cytometry analysis. In this way, the MCF-7 cells were harvested in the DMEM and washed in PBS. The cells were fixed in cold 70% ethanol for 30 minutes at 4°C. After that, MCF-7 cells were washed with 2X in PBS and spun at 2700 rpm in a centrifuge. The MCF-7 cells were treated with ribonuclease to ensure that only the DNA, and not RNA, is stained. Next, 200 µL PI was added to stock solution. Then, to identify single cells, the forward scatter (FS) and side scatter (SS) are measured by FlowJo software. The PBS containing MCF-7 cell lines without any NPs was used as a control group.

**RNA extraction, cDNA preparation and real-time PCR**

Total RNAs were isolated from MCF-7 cells by means of RNeasy plus mini kit (QIAGEN- Cat. No: 74134). Extracted RNA was treated with DNase I enzyme. One microgram of RNA from each sample was used for cDNA synthesis by reverse transcriptase. RNA samples were incubated at 65°C for 5 minutes with 1 µL Oligo dT (0.5 µg/µL) at a final volume of 10 µL, and then, mixed with 4 µL of 5X buffer, 0.5 µL RT Enzyme Mix I, 0.5 µL of random hexamer primer (6-mer) (100 µM) and, 4.5 µL of RNase Free dH₂O. Finally, the 0.2 µL of prepared buffer was used to PCR reaction. After incubation of the buffer at 42°C for 15 min, and at 85°C for 5 minutes, the mixture was transcribed into cDNA. The quality of cDNA is evaluated by electrophoresis assay. 2 µL cDNA of each sample was used for real-time PCR in 16 µL reaction mixtures with 6 µL of SYBR premix ex taq and 0.4 µL of specific forward and reverse primers. The forward β-actin (as a housekeeping gene) primer (5’-GCTCAGGAGGACAAAT-3’) and reverse β-actin (Forward primer: 5’-GCTCAGGAGGACAAAT-3’).
primer (5'-GGCATCCAGAAGACTAC-3') also were used to normalize the target gene expression. The reverse primer sequence of bax primers set was 5'-CAT CTT CTT CCA GAT GGT GA-3' and forward primer sequence was 5'-GTT TCA TCC AGG ATC GAG CAG-3'. Eventually, 0.25 μL of ROX (50X), 0.8 μL of cDNA and, 8 μL of dH2O are added to buffer. Initial denaturation step in real-time PCR was run at 95°C for 10 minutes. Second step was done with 40 cycles at 95°C for 15 seconds and 60°C for 1 second. The Melt Curve achieved at 95°C for 15 seconds, 60°C for 1 minutes and, 95°C for 15 seconds. The real-time PCR was performed in duplicate, and relative mRNA of each target gene was determined by using the formula 2^{-ΔCT} (CT, cycle threshold) where ΔCT = CT (target gene) − CT (β-actin). The comparative expression level of each target gene between different samples was calculated by 2^{-ΔΔCT} . In addition, melting curves used to determine non-specific amplification.

Statistical analysis
Statistical analysis was performed using GraphPad Prism, version 5.0. The significant difference between the experimental groups and controls was assessed by one-way ANOVA and post hoc Tukey test. The results were presented as mean ± standard deviation (SD). P value < 0.05 represented significant differences.

Results and Discussion
Physicochemical properties of NPs were investigated in this study are summarized in Table 1. The morphology and diameter of PLGA-PTX-VitD3 co-delivery NPs were done using SEM at an accelerating voltage of 20.0 KV (Philips XL-30). The diameter of PLGA-PTX-VitD3 co-delivery NPs measured 23146 ± nm (Figure 1a). The hydrodynamic diameter of PLGA-PTX-VitD3 co-delivery NPs was measured by DLS (Stereoscope-IN A-ONE Enc., Korea) <250 nm as shown in Figure 1b. The NPs were homogeneously dispersed. The zeta potential of NPs was -20 to -10 mV, which related to the presence of polyvinyl alcohol on the surface of the PLGA NPs. The zeta potential prevents the agglomeration of particles by using electrical repulsion (Table 1).

Figure 2 shows FT-IR spectra of PLGA (a), PLGA-PTX NPs (b) and PLGA-PTX- VitD3 co-delivery NPs (c). As shown in Figure 2a, the absorption band between 3600 cm⁻¹ and 3400 cm⁻¹ allocated both the νs (O-H) and νas (O-H) of hydroxyl group in PLGA NPs. The extreme absorption band between 2700 cm⁻¹ and 3000 cm⁻¹ allocated tensile vibration at δ (CH, CH2 e CH3). The shoulder between 1750 cm⁻¹ and 1760 cm⁻¹ showed a tensile vibration at δ (C=O). The absorption peaks between 1250 cm⁻¹ and 1500 cm⁻¹ indicated change shape of δ (CH2 e CH3). The absorption peaks between 1150 cm⁻¹ and 1300 cm⁻¹ were related to tensile vibration at δ (C=O). According to studies, the absorption peaks of PTX were between 3305 cm⁻¹ and 3479 cm⁻¹ of which were related to tensile vibration at δ (N-H). The tensile vibration at δ (C-H) is also shown between 2889 cm⁻¹ and 2970 cm⁻¹. The shoulder

Table 1. Physiochemical properties of PLGA, PLGA-PTX NPs, and PLGA-PTX- VitD3 co-delivery NPs

| Sample                | Size (nm) | PDI  | Zeta (mV) | Relative EE % | Relative DL (mg/g) |
|-----------------------|-----------|------|-----------|---------------|--------------------|
| PLGA NPs              | 60±09     | 0.02 | -18.4     | -             | -                  |
| PLGA-PTX NPs          | 200±27    | 0.04 | -20.3     | 85%           | 7                  |
| PLGA-PTX-VitD3 NPs    | 231±46    | 0.06 | -15.7     | PTX 82%       | PTX 6              |
|                       |           |      |           | VitD3 95%     | VitD3 1.5          |

PGLA, poly lactic glycolic acid; NPs, nanoparticles; PTX, paclitaxel.
between 1703 cm$^{-1}$ and 1732 cm$^{-1}$ was in regard to tensile vibration at δ (C=O).25 In current study, the absorption peaks of PTX and vitamin D are not observed in the FTIR spectrum of PLGA-PTX NPs (Figure 2b) and PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs (Figure 2c), which may indicate the complete encapsulation of PTX and vitamin D into the PLGA NPs.26

Cell viability assay revealed that PLGA NPs and PLGA-PTX NPs have no toxic effects on the MCF-7 cell line. As shown in Figure 3, the IC$\textsubscript{50}$ of PTX, and PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs against MCF-7 cell lines calculated 7.5 µg/mL and 8 µg/mL, respectively (Figure 3a). VitD$\textsubscript{3}$ did not show toxic effects at concentrations of about 1000 µg/mL (Figure 3b).

Madani et al at 2017 prepared PLGA-PTX NPs via single emulsion and precipitation methods with variable parameters including drug concentration, aqueous to organic phase volume ratio, polymer concentration, sonication time and PVA concentration.17 Cerqueira et al at 2017 prepared the PLGA NPs embedded with PTX and coated with hyaluronic acid (HA-PTX-PLGA) to target the drug to breast cancer cells. New formulation of HA-PTX-PLGA NPs showed high potential to decrease IC$\textsubscript{50}$ of PTX.27 Turino et al at 2017 prepared the PLGA-NPs, coated with L-ferritin, for the simultaneous delivery of PTX into MCF-7 cells. The results confirmed that NPs decolorated with L-feritin increased PTX cytotoxicity. Moreover, the coating increased NPs stability, thus reducing the fast release of a specific drug before reaching the target.28 Tran prepared dual anticancer agents such as PTX and artesunate (ART), which were loaded into PLGA NPs by solvent evaporation technique from oil-in-water emulsion, stabilized with Tween 80. The PTX and ART released from NPs in a controlled release pattern. Moreover, compared to free drugs, PTX and ART preparation increased cytotoxicity on breast cancer cell lines.29

Based on the results, there was no significant difference between the PTX release from PLGA-PTX NPs and the PTX release from PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs between 0.5 and 240 hours (P > 0.05) (Table 2, Figure 4). No significant difference release of the PTX from PLGA-PTX NPs was also observed between 0.5 and 3 hours (P > 0.05). The release of VitD$\textsubscript{3}$ from PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs between 0.5 and 12 hours did not also show meaningful differences (P > 0.05). Hence, the release of VitD$\textsubscript{3}$ from PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs increased at 240 hours, continuously (P < 0.05). The release of PTX and VitD$\textsubscript{3}$ from PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs showed a noticeable difference between 3 and 96 hours (P < 0.05) (Table 2, Figure 4).

Figure 5 shows the migration of MCF-7 cell line at the beginning (as a control) and after 24 hours of exposure, when exposed to PLGA-PTX-VitD$\textsubscript{3}$ NPs, PLGA-PTX NPs, and PTX. The results showed that PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs is able to prevent metastasis of the MCF-7 cell lines.

As we show in Figure 6, the nucleus of MCF-7 cell lines upon exposure to PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs become fragment and dense chromatin, which showed MCF-7 cells death.

Figure 7A shows the flow cytometer and cell cycle analysis of PLGA (a), PTX (b), PLGA-PTX NPs (c), PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs (d). We found that there was a significant difference between PTX, PLGA-PTX NPs, PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs, and the control group in the SUB G (1)/M phase (P = 0.030). The PLGA-PTX-VitD$\textsubscript{3}$ co-delivery NPs were able to induce early
Table 2. In vitro drug release from the optimized sample. The percentage of cumulative release of PTX from PLGA-PTX, PTX from Co-delivery NPs and vitamin D from Co delivery NPs against time

| Time (hour) | PTX from PLGA-PTX (a) | PTX from Co-delivery (b) | Vitamin D from Co-delivery (c) |
|------------|-----------------------|--------------------------|-------------------------------|
| 0.5        | 2.04 ± 0.32 (a)       | 3.00 ± 0.90 (b)          | 0 (c)                         |
| 1          | 5.67 ± 0.88 (a)       | 6.00 ± 1.90 (b)          | 0 (c)                         |
| 2          | 7.67 ± 1.17 (a)       | 10.73 ± 1.22 (b)         | 0 (c)                         |
| 3          | 12.23 ± 1.74 (a)      | 16.00 ± 5.51 (b)         | 0 (c)                         |
| 6          | 18.03 ± 2.65 (a)      | 20.00 ± 8.50 (b)         | 1.00 ± 0.00 (c)               |
| 12         | 23.00 ± 4.48 (a)      | 24.00 ± 3.51 (b)         | 3.00 ± 0.58 (c)               |
| 24         | 30.00 ± 3.06 (a)      | 35.00 ± 7.02 (b)         | 19.30 ± 1.56 (c)              |
| 48         | 38.00 ± 3.50 (a)      | 48.00 ± 7.44 (b)         | 34.00 ± 4.58 (c)              |
| 72         | 49.03 ± 6.20 (a)      | 54.00 ± 3.51 (b)         | 40.97 ± 6.72 (c)              |
| 96         | 55.97 ± 3.87 (a)      | 62.00 ± 4.04 (b)         | 46.00 ± 4.51 (c)              |
| 120        | 60.00 ± 2.73 (a)      | 66.00 ± 7.05 (b)         | 57.00 ± 7.51 (c)              |
| 144        | 69.00 ± 10.17 (a)     | 70.00 ± 7.51 (b)         | 64.97 ± 3.05 (c)              |
| 168        | 74.00 ± 3.51 (a)      | 80.17 ± 5.67 (b)         | 75.00 ± 7.21 (c)              |
| 240        | 92.00 ± 4.04 (a)      | 98.00 ± 2.00 (b)         | 96.00 ± 5.03 (c)              |

*Values are the means ± standard error (n=3). Different capital letters (A, B, C, ...) in the same row shows significant difference among treatments for each time and different lowercase letters (a, b, c, ...) in the same column shows significant difference among different times (Tukey’s test, P<0.05).

Kang et al found that anti-tumor activity of PTX from microemulsion containing PLGA was enhanced against MCF-7 cell lines.30 Shiny et al in 2013 prepared the PTX loaded microspheres using the blends of PLGA, poly-caprolactone. Shiny studies showed that blend of PLGA with poly-caprolactone resulted in complete release of the drug in a period of 30 days.31 Jin et al in 2009 also apoptosis on MCF-7 cells (41.425 ± 6.965) which showed a significant difference from the control group (11.245 ± 0.431) (P = 0.028). The results of this study also showed that PLGA-PTX, PTX and PLGA-PTX-VitD3 co-delivery NPs were able to block the MCF-7 cells at G (1)/M phase, which showed a significant difference in comparison with the control group (P < 0.05).

The results of this study showed that the expression of bax gene in the MCF-7 cells exposed to the PLGA-PTX-VitD3 co-delivery NPs was significantly higher than the control group. Gene expression level at the PLGA-PTX-VitD3 co-delivery NPs showed an increase in comparison with PTX (Figure 7B). The expression of the bax gene in the PLGA-PTX NPs also showed a significant increase compared to free PTX (Figure 7B).

Figure 4. PTX release from PLGA NPs (a), PTX release from co-delivery NPs (b) and VitD3 release from co-delivery NPs (c).

Figure 5. The mean of the distance scratch edges (n = 15) for PLGA-PTX-VitD3 co-delivery NPs (b), PLGA-PTX NPs (d), and PTX (f) at the beginning (a, c and e), and after 24 hours of experience.
prepared the PTX-loaded PLGA NPs and determined cytotoxicity of released PTX for MCF-7 cell lines. The PTX-loaded PLGA NPs demonstrated that released PTX retained its bioactivity to block cells in G2/M phase. Further, Vivek et al in 2014 investigated “smart” pH-responsive drug delivery system based on chitosan nano-carrier for its potential intelligent controlled release and enhancing chemotherapeutic efficiency of oxaliplatin. Furthermore, it was found that expression of \(bax\) gene was significantly up-regulated. This study does not concentrate on anti-tumor activity of \(\text{VitD}_3\) (as a confounder) loaded in the PLGA-PTX-Vit\(\text{D}_3\) co-delivery NPs. Indeed, we did not investigate the synergistic impact of \(\text{VitD}_3\) and PTX. The cytotoxic effects of vitamin D and PLGA against cancer cells have been studied separately. It would not be cost-efficient to do repetitive tests.

**Conclusion**

Current study showed that PTX and \(\text{VitD}_3\) were loaded completely into the PLGA NPs. Despite the fact that the toxicity of the PLGA-PTX-Vit\(\text{D}_3\) co-delivery NPs against MCF-7 cell lines became lower than that of free PTX, the co-deliver NPs were able to release drugs continuously for a long time which could increase the efficiency of drugs. The PLGA-PTX-Vit\(\text{D}_3\) co-delivery NPs not only was able to prevent the formation of metastasis, but also, they induced primary apoptosis in the MCF-7. Furthermore, we found that the PLGA-PTX-Vit\(\text{D}_3\) co-delivery NPs increased expression of \(bax\) gene in the MCF-7 cell lines.

**Ethical Issues**

This study was in accordance with the declaration of Helsinki; however, because we just used leftovers from primary cell line the need for ethical approval was not applicable.

**Conflict of Interest**

Authors declare no conflict of interest in this study.

**Acknowledgments**

We thank our colleagues from Guilan University of Medical Sciences who provided insight and expertise that greatly assisted the research although they may not agree with all of the interpretations/conclusions of this paper. We would also like to show our gratitude to Dr. Bahram Soltani for sharing their pearls of wisdom with us during the course of this research, and we thank 3 “anonymous” reviewers for their so-called insights. We gratefully acknowledge...
the dedicated efforts of the investigators and coordinators participated in this study.

References

1. Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. *Breast Cancer Res Treat* 2012;136(3):647-58. doi: 10.1007/s10549-012-2264-5

2. Nguyen KT. Targeted nanoparticles for cancer therapy: promises and challenge. *J Nanomedic Nanotechnol* 2011;2:103e. doi: 10.4172/2157-7439.1000103e

3. Zheng N, Lian B, Xu G, Liu X, Li X, Ji J. Development of a Subcellular Semimimechanism-Based Pharmacokinetic/Pharmaceutical Dynamic Model to Characterize Paclitaxel Effects Delivered by Polymeric Micelles. *J Pharm Sci* 2019;108(1):725-31. doi: 10.1016/j.xphs.2018.10.062

4. Venugopal V, Krishnan S, Palaminuthu V, Sankarananthy K, Kalaimani JK, Karupiah S, et al. Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer: In-vitro and in-vivo anticancer activities. *PLoS One* 2018;13(11):e0206109. doi: 10.1371/journal.pone.0206109

5. Vijayan V, Shalini K, Yugeshvaran V, Yee TH, Balakrishnan S, Palaminuthu V. Effect of paclitaxel-loaded PLGA nanoparticles on MDA-MB type cell lines: apoptosis and cytotoxicity studies. *Carr Pharm Dev* 2018;24(28):3366-75. doi: 10.2174/138161282466618090310301

6. Sadat Tabataee Mirakabad F, Nejati-Koshki K, Akbarzadeh A, Yamchi MR, Milani M, Zarghami N, et al. PLGA-based nanoparticles as cancer drug delivery systems. *Asian Pac J Cancer Prev* 2014;15(2):517-35. doi: 10.7314/apjcp.2014.15.2.517

7. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. *Carr Med Chem* 2004;11(4):413-24. doi: 10.2174/0929867043455909

8. Grabowski N, Hillaireau H, Vergnaud J, Santiago LA, Kerdine-Romer S, Pallardy M, et al. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. *Int J Pharm* 2013;452(2):686-94. doi: 10.1016/j.ijpharm.2013.05.025

9. Menon JU, Kona S, Wadajkar AS, Desai F, Vadla A, Nguyen KT. Effects of surfactants on the properties of PLGA nanoparticles. *J Biomed Mater Res A* 2012;100(8):1998-2005. doi: 10.1002/jbm.a.34040

10. Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. *Biomaterials* 2006;27(21):4025-33. doi: 10.1016/j.biomaterials.2006.03.006

11. Horwitz SB. Taxol (paclitaxel): mechanisms of action. *Ann Oncol* 1994;5 Suppl 6:S3-6.

12. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. *Clin Cancer Res* 2001;7(4):1043-51.

13. Koshigura K, Kolke M, Asou H, Cho SK, Stephen T, Rude RK, et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. *Breast Cancer Res Treat* 1999;53(2):113-20. doi: 10.1023/a:1006123819675

14. Krishnan AV, Swami S, Feldman D. Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. *J Steroid Biochem Mol Biol* 2010;121(1-2):343-8. doi: 10.1016/j.jsbmb.2010.02.009

15. Chakraborti CK. Vitamin D as a promising anticancer agent. *Indian J Pharmacol* 2011;43(2):113-20. doi: 10.4103/0253-7613.77335

16. Mathiasen IS, Lademann U, Jäättelä M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. *Cancer Res* 1999;59(19):4848-56.

17. Madani F, Esnaashari SS, Mupokoro B, Dorkoosh F, Khosravani M, Adabi M. Investigation of effective parameters on size of paclitaxel loaded PLGA nanoparticles. *Adv Pharm Bull* 2018;8(1):77-84. doi: 10.15171/apb.2018.010

18. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm* 2010;67(3):217-23.

19. Ahmadiankia N, Moghadam HK, Mishan MA, Bahrami AR, Naderi-Meshkin H, Bidkhori HR, et al. Berberine suppresses migration of MCF-7 breast cancer cells through down-regulation of chemokine receptors. *Iran J Basic Med Sci* 2016;19(2):125-31.

20. Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. *J Invest Dermatol* 2017;137(2):e11-e6. doi: 10.1016/j.jid.2016.11.020

21. Giaretti W. Model of Chromosomal Instability in Oral Carcinogenesis and Progression. Oral Cancer. InTech; 2012. doi: 10.5772/31883

22. Wiberley SE, Colthup NB, Daly L. *Introduction to Infrared and Raman Spectroscopy*. New York: Academic Press; 1975.

23. Silva ATCR, Cardoso BCO, e Silva MESR, Freitas RFS, Sousa RG. Synthesis, characterization, and study of PLGA copolymer in vitro degradation. *J Biomater Nanobiotechnol* 2015;6(1):8-19. doi: 10.4236/jbnn.2015.61002

24. Hummel DO, Scholl F, Solti A. Atlas of polymer and plastics analysis: plastics, fibres, rubbers, resins; starting and auxiliary materials, degradation products. Carl Hanser; 1988.

25. Yerlikaya F, Orgen A, Ural I, Guven O, Karaagaoglu E, Khan MA, et al. Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach. *J Pharm Sci* 2013;102(10):3748-61. doi: 10.1002/jps.23686

26. Alipour S, Montaseri H, Tahafghodi M. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery, *Colloids Surf B BioInterfaces* 2010;81(2):521-9. doi: 10.1016/j.colsurfb.2010.07.050

27. Cerqueira BBS, Lasham A, Shelling AN, Al-Kassas R. Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells. *Mater Sci Eng C Mater Biol Appl* 2017;76:593-600. doi: 10.1016/j.msec.2017.03.012

28. Turino LN, Ruggiero MR, Stefania R, Cutrin JC, Aime S, Geninatti Crich S. Ferritin decorated PLGA/paclitaxel loaded nanoparticles endowed with an enhanced toxicity.
toward MCF-7 breast tumor cells. *Bioconjuc Chem* 2017;28(4):1283-90. doi: 10.1021/acs.bioconjchem.7b00096

29. Tran BN, Nguyen HT, Kim JO, Yong CS, Nguyen CN. Developing combination of artemisin with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response. *Drug Dev Ind Pharm* 2017;43(12):1952-62. doi: 10.1080/03639045.2017.1357729

30. Kang BK, Chon SK, Kim SH, Jeong SY, Kim MS, Cho SH, et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. *Int J Pharm* 2004;286(1-2):147-56. doi: 10.1016/j.ijpharm.2004.08.008

31. Shiny J, Ramchander T, Goverdhan P, Habibuddin M, Aukunuru JV. Development and evaluation of a novel biodegradable sustained release microsphere formulation of paclitaxel intended to treat breast cancer. *Int J Pharm Investig* 2013;3(3):119-25. doi: 10.4103/2230-973x.119212

32. Jin C, Bai L, Wu H, Song W, Guo G, Dou K. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. *Pharm Res* 2009;26(7):1776-84. doi: 10.1007/s11095-009-9889-z

33. Vivek R, Thangam R, Nipunbabu V, Ponraj T, Kannan S. Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a "smart" drug delivery system to breast cancer cell therapy. *Int J Biol Macromol* 2014;65:289-97. doi: 10.1016/j.ijbiomac.2014.01.054